E2F4 and prostate carcinoma: In earlier investigations it has been demonstrated that E2F4 mutations had been associated with GACs, ulcerative colitis-associated neoplasms, colorectal carcinomas, endometrial cancers and prostatic carcinomas and that E2F4 expression did not assist in apoptosis [41].